Literature DB >> 21913446

[Ocular findings in Nijmegen breakage syndrome].

Mirosława Grałek1, Krystyna H Chrzanowska, Krystyna Kanigowska, Beata Kocyła-Karczmarewicz.   

Abstract

UNLABELLED: Nijmegen Breakage Syndrome (NBS) is a genomic instability disease caused by inherited mutations in the NBN/NBS1 gene. The clinical symptoms of NBS are: primary microcephaly, characteristic facial appearance, recurring respiratory tract infections caused by immune deficiency and extremely high risk of cancer development at early age.
PURPOSE: The aim of the study was to assess the vision organ in patients with NBS.
MATERIAL AND METHODS: Ophthalmological examination of 10 NBS patients was performed. The visual acuity, refractive errors, anterior and posterior segment of the eye ball test, tonometry and biometry were assessed.
RESULTS: Serious pathology of the sight organ in the study group were found, including upward slanting of the palpebral fissures, reduced visual acuity, small eyes, small cornea diameter, lens opacity, refractive errors.
CONCLUSIONS: The patients with Nijmegen breakage syndrome have significant sight organ abnormalities. These pathologies require long-term ophthalmologic care.

Entities:  

Mesh:

Year:  2011        PMID: 21913446

Source DB:  PubMed          Journal:  Klin Oczna        ISSN: 0023-2157


  2 in total

Review 1.  Ocular involvement in primary immunodeficiency diseases.

Authors:  Sima Hosseinverdi; Hassan Hashemi; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2013-11-30       Impact factor: 8.542

2.  Nbn and atm cooperate in a tissue and developmental stage-specific manner to prevent double strand breaks and apoptosis in developing brain and eye.

Authors:  Paulo M G Rodrigues; Paulius Grigaravicius; Martina Remus; Gabriel R Cavalheiro; Anielle L Gomes; Maurício Rocha-Martins; Mauricio R Martins; Lucien Frappart; David Reuss; Peter J McKinnon; Andreas von Deimling; Rodrigo A P Martins; Pierre-Olivier Frappart
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.